“We live in a system that favors high-profit medicines. Those are the only things in play, and they don’t work. They are failing,” says Dr. Pierre Kory, a pulmonary and critical care specialist. He’s the president of the Frontline COVID-19 Critical Care Alliance.
Two years into this pandemic, why haven’t there been more clinical trials of repurposed drugs to treat COVID-19?
“It’s not about ivermectin. It’s about the pharmaceutical industry capture of our agencies, and how our policies are all directed at suppressing and avoiding” the use of cheap, repurposed drugs, says Kory.